FABRY-DISEASE
Drug
GENZYME CORPORATION
Total Payments
$1.2M
Transactions
2,825
Doctors
1,629
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $434,116 | 1,087 | 791 |
| 2018 | $195,932 | 826 | 601 |
| 2017 | $574,971 | 912 | 641 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 286 | 90.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $63,000 | 1 | 5.2% |
| Food and Beverage | $46,906 | 2,537 | 3.9% |
| Education | $7.00 | 1 | 0.0% |
Payments by Type
Research
$1.1M
286 transactions
General
$109,913
2,539 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Fabry Disease Registry | GENZYME CORPORATION | $257,528 | 0 |
| Fabry Registry | GENZYME CORPORATION | $163,231 | 0 |
| Fabry LSD Data Registry | GENZYME CORPORATION | $163,095 | 0 |
| Q2 2017 Fabry LSD Registry | GENZYME CORPORATION | $146,948 | 0 |
| Q3 2017 Fabry LSD Registry | GENZYME CORPORATION | $133,372 | 0 |
| Q1 2017 Fabry LSD Registry | GENZYME CORPORATION | $91,570 | 0 |
| Q4 2016 Fabry LSD Registry | GENZYME CORPORATION | $66,927 | 0 |
| Fabry Disease Registry Protocol and Pregnancy Subregistry Protocol | GENZYME CORPORATION | $17,474 | 0 |
| Univ of Iowa LSD Registry Q3 2016 - Fabry | GENZYME CORPORATION | $16,097 | 0 |
| Q4 2016 Fabry LSD Registry | GENZYME CORPORATION | $8,375 | 0 |
| Q3 2016 Fabry LSD Registry | GENZYME CORPORATION | $8,044 | 0 |
| Fabry Disease Registry Protocol and Pregnancy Sub-Registry Protocol | SANOFI US SERVICES INC. | $6,120 | 0 |
| Fabry Disease Registry Protocol | GENZYME CORPORATION | $5,991 | 0 |
| Fabry Registry Program | GENZYME CORPORATION | $4,080 | 0 |
| IRB Annual Review | GENZYME CORPORATION | $2,040 | 0 |
| Fabry Disease Registry IRB fee for annual review | GENZYME CORPORATION | $1,329 | 0 |
| Rare Disease Registry Program | GENZYME CORPORATION | $875.00 | 0 |
| IRB Annual Review for Gaucher, Pompe, Fabry and MPSI Registry | GENZYME CORPORATION | $680.00 | 0 |
| IRB Continuing Review | GENZYME CORPORATION | $600.00 | 0 |
| LSD-Registry Protocol | GENZYME CORPORATION | $475.00 | 0 |
Top Doctors Receiving Payments for FABRY-DISEASE — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Nephrology | Orange, CT | $118.78 | 5 |
| , M.D | Nephrology | Brockton, MA | $117.61 | 6 |
| , MD | Nephrology | Orlando, FL | $116.29 | 6 |
| , M.D | Specialist | Houston, TX | $115.77 | 6 |
| , MD | Nephrology | Los Angeles, CA | $115.71 | 1 |
| , M.D | Pediatrics | Boston, MA | $113.41 | 6 |
| , MD | Nephrology | Raleigh, NC | $111.85 | 6 |
| , M.D | Nephrology | West Nyack, NY | $109.23 | 7 |
| , M.D., P.A | Nephrology | Houston, TX | $108.63 | 7 |
| Qaisar Shah | Neurology | Willow Grove, PA | $107.30 | 1 |
| Cary Shiwarski | Nephrology | Pittsburgh, PA | $103.28 | 2 |
| , MD | Pediatrics | Minneapolis, MN | $102.49 | 3 |
| , MD | Student in an Organized Health Care Education/Training Program | Wilson, NC | $102.21 | 6 |
| , M.D | Cardiovascular Disease | Bloomfield, CT | $101.99 | 5 |
| , MD | Cardiovascular Disease | Bloomfield, CT | $100.56 | 5 |
| , M.D | Clinical Genetics (M.D.) | Pittsburgh, PA | $100.01 | 1 |
| , M.D | Anesthesiology | Pittsburgh, PA | $100.01 | 1 |
| , M.D | Pediatrics | Brooklyn, NY | $100.01 | 1 |
| , M.D | Internal Medicine | Pittsburgh, PA | $100.01 | 1 |
| , MD | Clinical Biochemical Genetics | Chicago, IL | $100.00 | 1 |
| , MD | Neurology | Salt Lake City, UT | $100.00 | 1 |
| , MD | Neurology | Salt Lake City, UT | $100.00 | 1 |
| , M.D | Clinical Genetics (M.D.) | Cincinnati, OH | $100.00 | 1 |
| C Ronald Scott | Clinical Genetics (M.D.) | Seattle, WA | $100.00 | 1 |
| , M.D., J.D | Neurology | Milwaukee, WI | $100.00 | 1 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $1.2M
- SANOFI US SERVICES INC. $6,120
- Genzyme Corporation $17.83
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 1,629
- Transactions 2,825
About FABRY-DISEASE
FABRY-DISEASE is a drug associated with $1.2M in payments to 1,629 healthcare providers, recorded across 2,825 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2017 to 2019. In 2019, $434,116 was paid across 1,087 transactions to 791 doctors.
The most common payment nature for FABRY-DISEASE is "Unspecified" ($1.1M, 90.9% of total).
FABRY-DISEASE is associated with 20 research studies, including "Fabry Disease Registry" ($257,528).